Jaguar Health Approves Reverse Stock Split to Prevent Market Delisting
San Francisco, Monday, 27 April 2026.
Facing delisting, Jaguar Health will enact a 1-for-35 reverse stock split on April 30, 2026, aiming to boost its share price before a critical May 15 regulatory deadline.
The Mechanics of the Split and Nasdaq Requirements
To rectify its market standing, Jaguar Health, Inc. (Nasdaq: JAGX) will execute a 1-for-35 reverse stock split of its issued and outstanding common stock [1]. Approved during a Special Meeting of Stockholders in April 2026, the reclassified shares will begin trading at the market open on Thursday, April 30, 2026, under the new CUSIP number 47010C862 [1]. The corporate action will consolidate every 35 pre-split shares into a single post-split share without altering the par value, and shareholders will receive cash payments in lieu of any fractional shares [1]. Equiniti Trust Company, LLC has been appointed as the exchange agent to facilitate the transition for stockholders of record [1].
Financial Maneuvers and Strategic Licensing
While the reverse split addresses immediate regulatory pressures, Jaguar Health’s underlying financial architecture relies heavily on strategic partnerships and capital raises to fund its clinical pipeline [2]. In January 2026, the company secured a critical U.S. licensing agreement with Future Pak for its core products, Mytesi and Canalevia-CA1 [2]. This deal provided an immediate infusion of USD 16 million upfront, alongside USD 2 million in contingent funds and the potential for up to USD 20 million in future milestone payments [2]. Additionally, Jaguar Health received another USD 3 million from Future Pak in March 2026 following the termination of a buy-back provision [2].
Market Opportunities in Human and Animal Health
To diversify its revenue and capture broader market shares, Jaguar Health is aggressively pursuing follow-on indications for crofelemer across both human and animal health segments [2]. The financial incentives in these therapeutic areas are substantial. The global market for short bowel syndrome (SBS), a key target for the company’s pipeline, was valued at USD 1.65 billion in 2025 and is projected to grow to USD 2.7 billion by 2034 [2]. This represents an anticipated market expansion of 63.636 percent over the nine-year period. Furthermore, the broader global antidiarrheal market was valued at USD 102.15 billion in 2024 and is forecast to reach USD 145.67 billion by 2031 [2].
The Road Ahead for Jaguar Health
As the April 30, 2026, effective date for the reverse stock split approaches, Jaguar Health’s immediate priority is stabilizing its equity to satisfy Nasdaq’s stringent requirements [1]. The Nasdaq Hearings Panel retains the authority to defer its final compliance determination for up to 20 business days after the May 15 deadline, adding a layer of procedural waiting to the company’s timeline [1].